Inhibitors of cytochrome P450 4A suppress angiogenic responses

American Journal of Pathology

Volumn 166, Issue 2, 2005, Pages 615-624

  Chen, Ping ^a   Guo, Meng ^a   Wygle, Dana ^a   Edwards, Paul A ^a   Falck, John R ^c   Roman, Richard J ^d   Scicli, A Guillermo ^a,b  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID; CYTOCHROME P450 4A; DIBROMODODECENYL METHYLSULFONIMIDE; FIBROBLAST GROWTH FACTOR; FORMAMIDE DERIVATIVE; N HYDROXY N' (4 BUTYL 2 METHYLPHENOL)FORMAMIDINE; SULFONE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; CORNEA; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MITOGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REVASCULARIZATION; UMBILICAL VEIN;

EID: 13244292649     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62282-1     Document Type: Article

References (44)

1. Wheeler-Jones C, Abu-Ghazaleh R, Cospedal R, Houliston RA, Martin J, Zachary I: Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 1997, 420:28-32
2. Sa G, Murugesan G, Jaye M, Ivashchenko Y, Fox PL: Activation of cytosolic phospholipase A2 by basic fibroblast growth factor via a p42 mitogen-activated protein kinase-dependent phosphorylation pathway in endothelial cells. J Biol Chem 1995, 270:2360-2366
3. Warner LC, Hack N, Egan SE, Goldberg HJ, Weinberg RA, Skorecki KL: RAS is required for epidermal growth factor-stimulated arachidonic acid release in rat-1 fibroblasts. Oncogene 1993, 8:3249-3255
4. Thorsen VA, Vorland M, Bjorndal B, Bruland O, Holmsen H, Lillehaug JR: Participation of phospholipase D and alpha/beta-protein kinase C in growth factor-induced signalling in C3H10T1/2 fibroblasts. Biochim Biophys Acta 2003, 1632:62-71
5. Banan A, Zhang LJ, Shaikh M, Fields JZ, Farhadi A, Keshavarzian A: Key role of PLC-gamma in EGF protection of epithelial barrier against iNOS upregulation and F-actin nitration and disassembly. Am J Physiol 2003, 285:C977-C993
6. Roman RJ: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002, 82:131-185
7. Zhao X, Imig JD: Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 2003, 4:73-84
8. Sacerdoti D, Gatta A, McGiff JC: Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins Other Lipid Mediat 2003, 72:51-71
9. Lin F, Rios A, Falck JR, Belosludtsev Y, Schwartzman ML: 20-Hydroxyeicosatetraenoic acid is formed in response to EGF and is a mitogen in rat proximal tubule. Am J Physiol 1995, 269:F806-F816
10. Amaral SL, Maier KG, Schippers DN, Roman RJ, Greene AS: CYP4A Metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. Am J Physiol Heart Circ Physiol 2003, 284:H1528-H1535
11. Jiang M, Mezentsev A, Kemp R, Byun K, Falck JR, Miano JM, Nasjletti A, Abraham NG, Laniado-Schwartzman M: Smooth muscle-specific expression of CYP4A1 induces endothelial sprouting in renal arterial microvessels. Circ Res 2004, 94:167-174
12. Hack N, Margolis B, Schlessinger J, Skorecki K: Interaction of epidermal growth factor with vasoactive hormones in the regulation of phospholipase A2. J Basic Clin Physiol Pharmacol 1991, 2:161-182
13. Boccellino M, Giovane A, Servillo L, Balestrieri C, Quagliuolo L: Fatty acid mobilized by the vascular endothelial growth factor in human endothelial cells. Lipids 2002, 37:1047-1052
14. Shibuya M: Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. Cancer Sci 2003, 94:751-756
15. Muthalif MM, Benter IF, Karzoun N, Fatima S, Harper J, Uddin MR, Malik KU: 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci USA 1998, 95:12701-12706
16. Kranenburg O, Gebbink MF, Voest EE: Stimulation of angiogenesis by Ras proteins. Biochim Biophys Acta 2004, 1654:23-37
17. Mazure NM, Brahimi-Horn MC, Pouyssegur J: Protein kinases and the hypoxia-inducible factor-1, two switches in angiogenesis. Curr Pharm Des 2003, 9:531-541
18. Miyata N, Taniguchi K, Seki T, Ishimoto T, Sato-Watanabe M, Yasuda Y, Doi M, Kametani S, Tomishima Y, Ueki T, Sato M, Kameo K: HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol 2001, 133:325-329
19. Sato M, Ishii T, Kobayashi-Matsunaga Y, Amada H, Taniguchi K, Miyata N, Kameo K: Discovery of a N′-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Bioorg Med Chem Lett 2001, 11:2993-2995
20. Capdevila JH, Falck JR: Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat 2002, 68-69:325-344
21. Yu M, Cambj-Sapunar L, Kehl F, Maier KG, Takeuchi K, Miyata N, Ishimoto T, Reddy LM, Falck JR, Gebremedhin D, Harder DR, Roman RJ: Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur J Pharmacol 2004, 486:297-306
22. Alonso-Galicia M, Falck JR, Reddy KM, Roman RJ: 20-HETE agonists and antagonists in the renal circulation. Am J Physiol 1999, 277:F790-F796
23. Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, Schwartzman ML: Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 1998, 284:966-973
24. Volkin DB, Verticelli AM, Marfia KE, Burke CJ, Mach H, Middaugh CR: Sucralfate and soluble sucrose octasulfate bind and stabilize acidic fibroblast growth factor. Biochim Biophys Acta 1993, 1203:18-26
25. Carlsson J, Yuhas JM: Liquid-overlay culture of cellular spheroids. Recent Results Cancer Res 1984, 95:1-23
26. Hsu SC, Volpert OV, Steck PA, Mikkelsen T, Polverini PJ, Rao S, Chou P, Bouck NP: Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res 1996, 56:5684-5691
27. Lang I, Hoffmann C, Olip H, Pabst MA, Hahn T, Dohr G, Desoye G: Differential mitogenic responses of human macrovascular and microvascular endothelial cells to cytokines underline their phenotypic heterogeneity. Cell Prolif 2001, 34:143-155
28. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ: A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996, 37:1625-1632
29. Staton CA, Stribbling SM, Tazzyman S, Hughes R, Brown NJ, Lewis CE: Current methods for assaying angiogenesis in vitro and in vivo. Int J Exp Pathol 2004, 85:233-248
30. Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP: VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 2004, 45:368-374
31. Shaw JP, Chuang N, Yee H, Shamamian P: Polymorphonuclear neutrophils promote rFGF-2-induced angiogenesis in vivo. J Surg Res 2003, 109:37-42
32. Amaral SL, Papanek PE, Greene AS: Angiotensin II and VEGF are involved in angiogenesis induced by short-term exercise training. Am J Physiol 2001, 281:H1163-H1169
33. Nie D, Tang K, Diglio C, Honn KV: Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. Blood 2000, 95:2304-2311
34. Stoltz RA, Conners MS, Gerritsen ME, Abraham NG, Laniado-Schwartzman M: Direct stimulation of limbal microvessel endothelial cell proliferation and capillary formation in vitro by a corneal-derived eicosanoid. Am J Pathol 1996, 148:129-139
35. Michaelis UR, Fisslthaler B, Medhora M, Harder D, Fleming I, Busse R: Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J 2003, 17:770-772
36. Wiecha J, Reineker K, Reitmayer M, Voisard R, Hannekum A, Mattfeldt T, Waltenberger J, Hombach V: Modulation of Ca2+-activated K+ channels in human vascular cells by insulin and basic fibroblast growth factor. Growth Norm IGF Res 1998, 8:175-181
37. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9:669-676
38. Gliki G, Wheeler-Jones C, Zachary I: Vascular endothelial growth factor induces protein kinase C (PKC)-dependent Akt/PKB activation and phosphatidylinositol 3′-kinase-mediates PKC delta phosphorylation: role of PKC in angiogenesis. Cell Biol Int 2002, 26:751-759
39. Uchiba M, Okajima K, Dike Y, Ito Y, Fukudome K, Isobe H, Suda T: Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ Res 2004 95:34-41
40. Lange A, Gebremedhin D, Narayanan J, Harder D: 20-Hydroxyeicosatetraenoic acid-induced vasoconstriction and inhibition of potassium current in cerebral vascular smooth muscle is dependent on activation of protein kinase C. J Biol Chem 1997, 272:27345-27352
41. Sun CW, Falck JR, Harder DR, Roman RJ: Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension 1999, 33:414-418
42. Shimizu K, Oku N: Cancer anti-angiogenic therapy. Biol Pharm Bull 2004, 27:599-605
43. Schmidek HH, Nielsen SL, Schiller AL, Messer J: Morphological studies of rat brain tumors induced by N-nitrosomethylurea. J Neurosurg 1971, 34:335-340
44. Barth RF: Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 1998, 36:91-102